Baricitinib was found to be an effective treatment for patchy alopecia areata (AA), in a retrospective study, with most patients experiencing hair regrowth after 4 to 16 weeks of treatment.
People with alopecia areata who experience hair regrowth may also see improvements in their quality of life and mental health, according to a new study.
1. In this randomized controlled trial, the Janus kinase (JAK) inhibitor baricitinib was associated with preserved β-cell function compared to placebo in patients with new-onset type 1 diabetes mellitus (T1DM). 2. Patients receiving baricitinib also demonstrated tighter glycemic control compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: The mainstay of T1DM treatment is
Baricitinib is more commonly prescribed by dermatologists for patients with alopecia in the United States and is projected to maintain a substantial market lead over ritlecitinib.